Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 74.256
2.
Mo Med ; 121(2): 124-125, 2024.
Article En | MEDLINE | ID: mdl-38694610
4.
Eur J Endocrinol ; 190(5): G25-G51, 2024 May 02.
Article En | MEDLINE | ID: mdl-38714321

Glucocorticoids are widely prescribed as anti-inflammatory and immunosuppressive agents. This results in at least 1% of the population using chronic glucocorticoid therapy, being at risk for glucocorticoid-induced adrenal insufficiency. This risk is dependent on the dose, duration and potency of the glucocorticoid, route of administration, and individual susceptibility. Once glucocorticoid-induced adrenal insufficiency develops or is suspected, it necessitates careful education and management of affected patients. Tapering glucocorticoids can be challenging when symptoms of glucocorticoid withdrawal develop, which overlap with those of adrenal insufficiency. In general, tapering of glucocorticoids can be more rapidly within a supraphysiological range, followed by a slower taper when on physiological glucocorticoid dosing. The degree and persistence of HPA axis suppression after cessation of glucocorticoid therapy are dependent on overall exposure and recovery of adrenal function varies greatly amongst individuals. This first European Society of Endocrinology/Endocrine Society joint clinical practice guideline provides guidance on this clinically relevant condition to aid clinicians involved in the care of patients on chronic glucocorticoid therapy.


Adrenal Insufficiency , Endocrinology , Glucocorticoids , Humans , Glucocorticoids/adverse effects , Glucocorticoids/therapeutic use , Glucocorticoids/administration & dosage , Adrenal Insufficiency/diagnosis , Adrenal Insufficiency/chemically induced , Adrenal Insufficiency/therapy , Adrenal Insufficiency/drug therapy , Endocrinology/standards , Endocrinology/methods , Europe , Societies, Medical/standards
7.
Front Endocrinol (Lausanne) ; 15: 1383681, 2024.
Article En | MEDLINE | ID: mdl-38706696

Rickets results from impaired mineralization of growing bone due to alterations in calcium and phosphate homeostasis. Clinical signs of rickets are related to the age of the patient, the duration of the disease, and the underlying disorder. The most common signs of rickets are swelling of the wrists, knees or ankles, bowing of the legs (knock-knees, outward bowing, or both) and inability to walk. However, clinical features alone cannot differentiate between the various forms of rickets. Rickets includes a heterogeneous group of acquired and inherited diseases. Nutritional rickets is due to a deficiency of vitamin D, dietary calcium or phosphate. Mutations in genes responsible for vitamin D metabolism or function, the production or breakdown of fibroblast growth factor 23, renal phosphate regulation, or bone mineralization can lead to the hereditary form of rickets. This position paper reviews the relevant literature and presents the expertise of the Bone and Mineral Metabolism Group of the Italian Society of Pediatric Endocrinology and Diabetology (SIEDP). The aim of this document is to provide practical guidance to specialists and healthcare professionals on the main criteria for diagnosis, treatment, and management of patients with rickets. The various forms of rickets are discussed, and detailed references for the discussion of each form are provided. Algorithms to guide the diagnostic approach and recommendations to manage patients with rare forms of hereditary rickets are proposed.


Endocrinology , Rickets , Humans , Rickets/diagnosis , Rickets/therapy , Rickets/metabolism , Endocrinology/methods , Endocrinology/standards , Italy , Vitamin D/metabolism , Vitamin D/therapeutic use , Child , Societies, Medical/standards , Disease Management
...